Christopher Walkey, Ph.D.
Education
- BSc from Simon Fraser University
- 12/1992 - Burnaby, BC, Canada
- Biochemistry
- PhD from University of Alberta
- 06/1998 - Edmonton, AB, Canada
- Postdoctoral Fellowship at Dana-Farber Cancer Insitute and Harvard Medical School
- Boston, Massachusetts, United States
Professional Interests
- Somatic genome editing
- Gene therapy and vector development
- Lipid and lipoprotein metabolism
Selected Publications
-
Walkey CJ, Lagor WR. " CaMKIIδ gene editing- A base hit for the heart " J Cardiovasc Aging. 2023 Mar ; 3 (2) : 19.
Pubmed PMID: 37065676. -
Huang Q, Chen AT, Chan KY, Sorensen H, Barry AJ, Azari B, Zheng Q, Beddow T, Zhao B, Tobey IG, Moncada-Reid C, Eid F, Walkey CJ, Ljungberg MC, Lagor WR, Heaney JD, Chan YA, Deverman BE. " Targeting AAV vectors to the central nervous system by engineering capsid-receptor interactions that enable crossing of the blood-brain barrier. " PLOS Biology. 2023 May ; in press
-
Lorincz R, Alvarez AB, Walkey CJ, Mendonça SA, Lu ZH, Martinez AE, Ljungberg C, Heaney JD, Lagor WR, Curiel DT. " In vivo editing of the pan-endothelium by immunity evading simian adenoviral vector " Biomed Pharmacother. 2023 Feb ; 158 : 114189.
Pubmed PMID: 36587560. -
Phillips E, Ahmad N, Sun L, Iben J, Walkey CJ, Rusin A, Yuen T, Rosen CJ, Willis IM, Zaidi M, Johnson DL. " MAF1, a repressor of RNA polymerase III-dependent transcription, regulates bone mass " eLife. 2022 May ; 11 : e74740.
Pubmed PMID: 35611941.
Memberships
- American Society for Gene and Cell Therapy
Log In to edit your profile